BOB ICB
Menu
  • Home
  • About us
    • What is the Integrated Care System?
    • Our Board & Leadership
    • Board Meetings
      • Board Papers
    • Information Governance and Data Protection Policies
      • DPIAs
    • Who is Involved?
    • Get Involved
    • ICB Structure
  • Our places
  • Your health
    • Cataract surgery - your choices
    • Dentists
    • Continuing Healthcare
    • Personalised Care
      • Public
      • Professionals
    • Clinical Commissioning Policy Statements & IFRs
  • How we work
    • Key Publications
    • BOB ICB Newsletter
    • Constitution & Governance Arrangements
    • Register of Interests
    • Fair Processing Notice
    • Freedom of Information Requests
    • Expenditure Over £25K
    • Medicines Optimisation
    • Counter Fraud
    • NHS Community pharmacy, optometry and dental commissioning and complaints
    • Digital & Data
  • Our strategies and plans
    • Primary Care Strategy
    • Integrated Care Strategy
    • Joint Forward Plan
    • Local Transformation Plan
  • News
  • Contact us
    • Make a complaint
    • Safeguarding
    • Subject Access Requests
    • Freedom of Information Requests
    • Accessibility Statement
  • Home
  • Staff Zone
    • Login
  1. Home
  2. Clinical Commissioning Policy Statement Categories
  3. Rheumatology

Rheumatology

Buckinghamshire

  • TVPC46 - Sequential use of biologic therapies and Janus-associated tyrosine kinases (JAK) inhibitors in Psoriatic Arthritis – INTERIM POLICY
  • TVPC51 -  Use of biological and immunomodulatory therapies in Rheumatoid Arthritis - INTERIM POLICY
  • TVPC92 - Biologic drugs for the management of axial spondyloarthritis
  • TVPC103 - Use of biological and immunomodulatory therapies in moderate Rheumatoid Arthritis – INTERIM POLICY

Oxfordshire

  • TVPC46 - Sequential use of biologic therapies and Janus-associated tyrosine kinases (JAK) inhibitors in Psoriatic Arthritis – INTERIM POLICY
  • TVPC51 -  Use of biological and immunomodulatory therapies in Rheumatoid Arthritis - INTERIM POLICY
  • TVPC92 - Biologic drugs for the management of axial spondyloarthritis
  • TVPC103 - Use of biological and immunomodulatory therapies in moderate Rheumatoid Arthritis – INTERIM POLICY

Berkshire West

  • TVPC46 - Sequential use of biologic therapies and Janus-associated tyrosine kinases (JAK) inhibitors in Psoriatic Arthritis – INTERIM POLICY
  • TVPC51 -  Use of biological and immunomodulatory therapies in Rheumatoid Arthritis - INTERIM POLICY
  • TVPC92 - Biologic drugs for the management of axial spondyloarthritis
  • TVPC103 - Use of biological and immunomodulatory therapies in moderate Rheumatoid Arthritis – INTERIM POLICY

Clinical Commissioning Policy Statement Categories

  • Aesthetics/Cosmetics
  • Complementary & Alternative Therapies
  • Dermatology
  • Ear, Nose & Throat (ENT)
  • Endocrinology
  • Gastroenterology
  • General Surgery
  • Guidance for Policy Exceptions
  • Infertility
  • Medicines
  • Mental Health
  • Musculoskeletal (MSK)
  • Neurology
  • NHS England
  • NICE Policies
  • Obstetrics & Gynaecology
  • Ophthalmology
  • Paediatrics & Child Health
  • Plastic Surgery
  • Podiatry
  • Private to NHS Funding
  • Radiology
  • Research Trial & NHS Funding
  • Rheumatology
  • Smoking Cessation before Planned Surgery
  • Urology
  • Vascular
  • © BOB ICB 2024 All rights reserved.
  • Accessibility
  • Cookie Policy
  • Site content & design: SCW CSU